Ruboxistaurin

Generic Name: Ruboxistaurin

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₂₈N_₄O_₃

CAS Number: 169939-94-0

Unique Ingredient Identifier: 721809WQCP

Background: Ruboxistaurin has been investigated for the basic science of Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus.

Clinical Trials

Randomized Study Using SM-030 Gel for Adults With Melasma

Phase 2

Recruiting

Conditions: Melasma

Interventions: Drug: SM-030 gel 0.64%
Drug: Placebo gel
Drug: SM-030 gel 0.08%

First Posted Date: 2024-06-12

Last Posted Date: 2024-12-13

Lead Sponsor: DermBiont, Inc.

Target Recruit Count: 138

Registration Number: NCT06454747

Locations: 🇸🇻
Centro de Investigación y Desarrollo Brioso Ramirez, Santa Tecla, La Libertad, El Salvador, El Salvador
🇸🇻
Zepeda Dermatologia, Santa Tecla, La Libertad, El Salvador

Randomized and Open Label Study for Safety and Efficacy of DBI-102 vs. Vehicle vs. Hydroquinone on Skin Pigmentation and Lentigos

Phase 2

Completed

Conditions: Hyperpigmentation

Interventions: Drug: Vehicle gel
Drug: DBI-102
Drug: Hydroquinone Cream

First Posted Date: 2022-08-23

Last Posted Date: 2023-10-25

Lead Sponsor: DermBiont, Inc.

Target Recruit Count: 75

Registration Number: NCT05511948

Locations: 🇸🇻
Zepeda Dermatologia, Santa Tecla, La Libertad, El Salvador

Ruboxistaurin in New York Heart Failure Classification III-IV Patients

Phase 1

Withdrawn

Conditions: Heart Failure

Interventions: Drug: Ruboxistaurin

First Posted Date: 2016-05-11

Last Posted Date: 2022-06-06

Lead Sponsor: University of Tennessee

Registration Number: NCT02769611

Locations: 🇺🇸
The Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio, United States

Signaling Mechanisms and Vascular Function in Diabetes Mellitus

Phase 2

Completed

Conditions: Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Ruboxistaurin

First Posted Date: 2008-09-30

Last Posted Date: 2008-09-30

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 30

Registration Number: NCT00761852

Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study

Phase 3

Completed

Conditions: Diabetic Retinopathy

Interventions: Drug: placebo
Drug: ruboxistaurin

First Posted Date: 2008-01-30

Last Posted Date: 2016-10-06

Lead Sponsor: Chromaderm, Inc.

Target Recruit Count: 685

Registration Number: NCT00604383

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT -5 hours, EST) or speak with your personal physician., Indianapolis, Indiana, United States

Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: ruboxistaurin
Other: placebo

First Posted Date: 2007-11-01

Last Posted Date: 2016-07-26

Lead Sponsor: Chromaderm, Inc.

Target Recruit Count: 48

Registration Number: NCT00552227

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 am to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States

Effect of LY333531 on Vascular and Neural Functions

Phase 2

Completed

Conditions: Diabetes Mellitus

First Posted Date: 2007-06-06

Last Posted Date: 2016-07-26

Lead Sponsor: Chromaderm, Inc.

Target Recruit Count: 30

Registration Number: NCT00482976

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boston, Massachusetts, United States

Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: ruboxistaurin
Drug: placebo

First Posted Date: 2006-02-28

Last Posted Date: 2016-08-29

Lead Sponsor: Chromaderm, Inc.

Target Recruit Count: 20

Registration Number: NCT00297401

Locations: 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physcian., Toronto, Ontario, Canada

Treatment for Completers of the Study B7A-MC-MBCM

Phase 3

Completed

Conditions: Diabetic Retinopathy

Interventions: Drug: Ruboxistaurin

First Posted Date: 2005-12-19

Last Posted Date: 2016-10-06

Lead Sponsor: Chromaderm, Inc.

Target Recruit Count: 203

Registration Number: NCT00266695

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Madison, Wisconsin, United States

The Effect of Ruboxistaurin on Small Fiber Function

Phase 2

Completed

Conditions: Diabetic Neuropathy

First Posted Date: 2005-09-19

Last Posted Date: 2016-07-26

Lead Sponsor: Chromaderm, Inc.

Target Recruit Count: 52

Registration Number: NCT00190970

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Norfolk, Virginia, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy